Federal court Zantac lawsuits were dismissed after ... and independent laboratories shows that one ranitidine 300 mg tablet can contain tens of thousands of nanograms (ng) of NDMA, greatly ...
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
WJET Erie on MSN2d
Drugmaker to settle nearly 80K Zantac lawsuits for up to $2.2 billionUK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
In its release, the FDA noted that samples of the drug known as ranitidine, also sold under the brand name Zantac, tested positive for a potentially cancer-causing agent called N ...
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK plc (LSE/NYSE: GSK) today announced that it has reached agreements with 10 plaintiff firms who together represent 93% (approximately 80,000) of the Zantac (ranitidine) state court product ...
The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer has agreed to settle most of the Zantac cases against it in state court ...
The agency cited concerns that ranitidine could degrade into NDMA, a carcinogen, over time or when exposed to heat. Pfizer has agreed to settle most of the Zantac cases against it in state court ...
Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback